Entity Common Stock, Shares Outstanding of Revance Therapeutics, Inc. from 13 May 2014 to 31 Oct 2024

Taxonomy & unit
dei: shares
Description
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
Summary
Revance Therapeutics, Inc. quarterly Entity Common Stock, Shares Outstanding in shares history and change rate from 13 May 2014 to 31 Oct 2024.
  • Revance Therapeutics, Inc. Entity Common Stock, Shares Outstanding for the quarter ending 31 Oct 2024 was 104,902,388, a 19% increase year-over-year.
Source SEC data
View on sec.gov
Entity Common Stock, Shares Outstanding, Quarterly (shares)
Entity Common Stock, Shares Outstanding, YoY Quarterly Change (%)

Revance Therapeutics, Inc. Quarterly Entity Common Stock, Shares Outstanding (shares)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2024 104,902,388 +17,088,908 +19% 31 Oct 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 104,823,331 +16,867,974 +19% 31 Jul 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 104,448,502 +20,408,150 +24% 30 Apr 2024 10-Q 09 May 2024 2024 Q1
Q3 2023 87,813,480 +5,539,898 +6.7% 31 Oct 2023 10-Q 08 Nov 2023 2023 Q3
Q2 2023 87,955,357 +14,849,664 +20% 31 Jul 2023 10-Q 08 Aug 2023 2023 Q2
Q1 2023 84,040,352 +11,272,191 +15% 28 Apr 2023 10-Q 09 May 2023 2023 Q1
Q3 2022 82,273,582 +10,478,730 +15% 31 Oct 2022 10-Q 08 Nov 2022 2022 Q3
Q2 2022 73,105,693 +1,275,975 +1.8% 29 Jul 2022 10-Q 09 Aug 2022 2022 Q2
Q1 2022 72,768,161 +1,238,794 +1.7% 29 Apr 2022 10-Q 10 May 2022 2022 Q1
Q3 2021 71,794,852 +5,245,678 +7.9% 28 Oct 2021 10-Q 09 Nov 2021 2021 Q3
Q2 2021 71,829,718 +5,901,422 +9% 28 Jul 2021 10-Q 05 Aug 2021 2021 Q2
Q1 2021 71,529,367 +14,477,321 +25% 27 Apr 2021 10-Q 10 May 2021 2021 Q1
Q4 2020 71,377,818 +14,451,067 +25% 12 Feb 2021 10-K 25 Feb 2021 2020 FY
Q3 2020 66,549,174 +21,440,814 +48% 30 Oct 2020 10-Q 09 Nov 2020 2020 Q3
Q2 2020 65,928,296 +21,825,764 +49% 24 Jul 2020 10-Q 06 Aug 2020 2020 Q2
Q1 2020 57,052,046 +13,045,466 +30% 24 Apr 2020 10-Q 07 May 2020 2020 Q1
Q4 2019 56,926,751 13 Feb 2020 10-K 26 Feb 2020 2019 FY
Q3 2019 45,108,360 +8,120,693 +22% 24 Oct 2019 10-Q 04 Nov 2019 2019 Q3
Q2 2019 44,102,532 +7,164,641 +19% 26 Jul 2019 10-Q 06 Aug 2019 2019 Q2
Q1 2019 44,006,580 +7,222,684 +20% 03 May 2019 10-Q 09 May 2019 2019 Q1
Q3 2018 36,987,667 +6,052,979 +20% 25 Oct 2018 10-Q 02 Nov 2018 2018 Q3
Q2 2018 36,937,891 +6,118,702 +20% 27 Jul 2018 10-Q 03 Aug 2018 2018 Q2
Q1 2018 36,783,896 +6,510,418 +22% 27 Apr 2018 10-Q 09 May 2018 2018 Q1
Q3 2017 30,934,688 +2,419,618 +8.5% 26 Oct 2017 10-Q 03 Nov 2017 2017 Q3
Q2 2017 30,819,189 +2,334,254 +8.2% 27 Jul 2017 10-Q 04 Aug 2017 2017 Q2
Q1 2017 30,273,478 +1,840,270 +6.5% 27 Apr 2017 10-Q 09 May 2017 2017 Q1
Q3 2016 28,515,070 +452,837 +1.6% 26 Oct 2016 10-Q 04 Nov 2016 2016 Q3
Q2 2016 28,484,935 +4,534,416 +19% 29 Jul 2016 10-Q 05 Aug 2016 2016 Q2
Q1 2016 28,433,208 +4,498,376 +19% 26 Feb 2016 10-K 04 Mar 2016 2015 FY
Q3 2015 28,062,233 +4,342,331 +18% 09 Nov 2015 10-Q 10 Nov 2015 2015 Q3
Q2 2015 23,950,519 +457,047 +1.9% 29 Jul 2015 10-Q 07 Aug 2015 2015 Q2
Q1 2015 23,934,832 +5,234,448 +28% 28 Feb 2015 10-K 04 Mar 2015 2014 FY
Q3 2014 23,719,902 05 Nov 2014 10-Q 13 Nov 2014 2014 Q3
Q2 2014 23,493,472 01 Aug 2014 10-Q 13 Aug 2014 2014 Q2
Q1 2014 18,700,384 13 May 2014 10-Q 14 May 2014 2014 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.